Arcturus Therapeutics Holdings Inc. (ARCT) P/E Ratio History
Historical price-to-earnings valuation from 2022 to 2023
Loading P/E history...
ARCT Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Arcturus Therapeutics Holdings Inc. (ARCT) trades at a price-to-earnings ratio of -3.7x, with a stock price of $8.90 and trailing twelve-month earnings per share of $-2.40.
The current P/E is 116% below its 5-year average of 23.4x. Over the past five years, ARCT's P/E has ranged from a low of 5.9x to a high of 70.7x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, ARCT trades at a 117% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, ARCT trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ARCT DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ARCT P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $39B | 127.0 | - | +207%Best | |
| $74B | 17.1Lowest | 2.70Best | +8% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
ARCT Historical P/E Data (2022–2023)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $25.55 | $3.61 | 7.1x | -70% |
| FY2023 Q2 | Fri Jun 30 2023 00:00:00 GM | $28.68 | $2.92 | 9.8x | -58% |
| FY2023 Q1 | Fri Mar 31 2023 00:00:00 GM | $23.97 | $4.08 | 5.9x | -75% |
| FY2022 Q4 | Sat Dec 31 2022 00:00:00 GM | $16.96 | $0.24 | 70.7x | +203% |
Average P/E for displayed period: 23.4x
See ARCT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ARCT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ARCT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonARCT — Frequently Asked Questions
Quick answers to the most common questions about buying ARCT stock.
Is ARCT stock overvalued or undervalued?
ARCT trades at -3.7x P/E, below its 5-year average of 23.4x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does ARCT's valuation compare to peers?
Arcturus Therapeutics Holdings Inc. P/E of -3.7x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is ARCT's PEG ratio?
ARCT PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2022-2023.